For patients who require hemodialysis access, 38% of them require grafts such as CryoVein and CryoArtery as an alternative to an autologous AV fistula.1 Up to 19% of patients with a synthetic hemodialysis graft have a graft infection.2 CryoVein and CryoArtery are ideal solutions to treat these infections and potentially save the hemodialysis site.3
The Ideal Grafts for:
- Patients in whom an autologous AV fistula is not possible
- Treating infected AV access grafts
- Patients who are at risk of AV access infections
- Patients with a limited number of AV access sites
- 72% cumulative patency at 24 months4
- Excellent resistance to infection4
- Outstanding durability5
- Same pulsatile flow dynamics & compliance as autografts6
||6mm - 15mm
||10cm - 30+mm
||4mm - 5+mm
||10cm - 30+mm
||3mm - 6mm*
||20cm - 80+cm*
1. Scott E et al. Conduits for hemodialysis access. J Sem Vasc Surg 2007;158-163.
2. Akoh J. Prosthetic arteriovenous grafts for hemodialysis. J Vasc Access 2009;10:137-47.
3. Lin P et al. Management of infected hemodialysis access grafts using cryopreserved human vein allografts. Am J Surg 2002;184:31-6.
4. CryoLife data on file (ML0101).
5. Brown K et al. Arterial reconstruction with cryopreserved human allografts in the setting of infection: a single-center experience with midterm follow-up. J Vasc Surg 2009;49:660-6.
6. Bia D et al. Differential function coupling between human saphenous cryoallografts and arteries: importance of the arterial type and the biomechanical parameter evaluated. Artif Organs 2007;31(11):809-818.